1. When Would You Use Single Inhaler Triple Therapy in COPD?

2. Objectives of Treatment

3. GOLD 2018: Pharmacologic Treatment Recommendations

4. GOLD 2018: Pharmacologic Treatment Recommendations (cont)

5. GOLD 2018: Pharmacologic Treatment Recommendations in Groups C and D

6. Anti-Inflammatory Therapy in Stable COPD

7. WISDOM: Exacerbation Risk in Patients With Prior Exacerbations and Elevated Blood Eosinophils

8. Blood Eosinophils and Prediction of ICS Effects

9. Anti-Inflammatory Therapy in Stable COPD

10. Associated Measures

11. Associated Measures (cont)

12. Individualized Benefit-Risk Assessment

13. Triple Inhaled Therapy

14. GOLD 2018: Pharmacologic Treatment Recommendations in Groups C and D

15. Advantages of a Single Inhaler Therapy

16. LABA/LAMA/ICS vs LABA/ICS and LABA/LAMA in the IMPACT Trial

17. IMPACT: Incidence of Pneumonia

18. LABA/LAMA/ICS vs LABA/ICS and LABA/LAMA in the IMPACT Trial

19. LABA/LAMA/ICS vs LABA/LAMA in the TRIBUTE Trial

20. LABA/LAMA/ICS vs LABA/LAMA in the TRIBUTE Trial (cont)

21. Main Adverse Events in the TRIBUTE Trial

22. Advantages of a Single Inhaler Therapy

23. Adherence to Inhaled Therapy and Mortality

24. GOLD 2018: Pharmacologic Treatment Recommendations in Groups C and D

25. Conclusion

26. Abbreviations

27. Abbreviations (cont)